Your browser doesn't support javascript.
loading
BRAT1-related disorders: phenotypic spectrum and phenotype-genotype correlations from 97 patients.
Engel, Camille; Valence, Stéphanie; Delplancq, Geoffroy; Maroofian, Reza; Accogli, Andrea; Agolini, Emanuele; Alkuraya, Fowzan S; Baglioni, Valentina; Bagnasco, Irene; Becmeur-Lefebvre, Mathilde; Bertini, Enrico; Borggraefe, Ingo; Brischoux-Boucher, Elise; Bruel, Ange-Line; Brusco, Alfredo; Bubshait, Dalal K; Cabrol, Christelle; Cilio, Maria Roberta; Cornet, Marie-Coralie; Coubes, Christine; Danhaive, Olivier; Delague, Valérie; Denommé-Pichon, Anne-Sophie; Di Giacomo, Marilena Carmela; Doco-Fenzy, Martine; Engels, Hartmut; Cremer, Kirsten; Gérard, Marion; Gleeson, Joseph G; Heron, Delphine; Goffeney, Joanna; Guimier, Anne; Harms, Frederike L; Houlden, Henry; Iacomino, Michele; Kaiyrzhanov, Rauan; Kamien, Benjamin; Karimiani, Ehsan Ghayoor; Kraus, Dror; Kuentz, Paul; Kutsche, Kerstin; Lederer, Damien; Massingham, Lauren; Mignot, Cyril; Morris-Rosendahl, Déborah; Nagarajan, Lakshmi; Odent, Sylvie; Ormières, Clothilde; Partlow, Jennifer Neil; Pasquier, Laurent.
Afiliación
  • Engel C; Centre de Génétique Humaine, Centre Hospitalier Régional Universitaire, Université de Franche-Comté, Besançon, France. cengel@chu-besancon.fr.
  • Valence S; Service de Neurologie Pédiatrique, Hôpital Armand Trousseau, APHP Sorbonne Université, Paris, France.
  • Delplancq G; Centre de Génétique Humaine, Centre Hospitalier Régional Universitaire, Université de Franche-Comté, Besançon, France.
  • Maroofian R; Department of Neuromuscular Diseases UCL Queen Square Institute of Neurology, University College London, London, UK.
  • Accogli A; Department of Specialized Medicine, Division of Medical Genetics, McGill University Health Centre, Montreal, QC, Canada.
  • Agolini E; Laboratory of Medical Genetics, Translational Cytogenomics Research Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
  • Alkuraya FS; Department of Translational Genomics, Center for Genomic Medicine, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
  • Baglioni V; Department of Human Neurosciences, Institute of Child and Adolescent Neuropsychiatry, Sapienza University of Rome, Rome, Italy.
  • Bagnasco I; Division of Neuropsychiatry, Epilepsy Center for Children, Martini Hospital, 10141, Turin, Italy.
  • Becmeur-Lefebvre M; Service de Génétique Clinique, CHR d'Orléans, Orléans, France.
  • Bertini E; Unit of Neuromuscular and Neurodegenerative Disorders, Department of Neurosciences, Bambino Gesù Children's Hospital IRCCS, Rome, Italy.
  • Borggraefe I; Department of Pediatric Neurology, Developmental Medicine and Social Pediatrics, University of Munich, 80337, Munich, Germany.
  • Brischoux-Boucher E; Centre de Génétique Humaine, Centre Hospitalier Régional Universitaire, Université de Franche-Comté, Besançon, France.
  • Bruel AL; UMR 1231 GAD, Inserm, Université de Bourgogne Franche Comté, Dijon, France.
  • Brusco A; Unité Fonctionnelle Innovation en Diagnostic Génomique des Maladies Rares, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.
  • Bubshait DK; Department of Medical Sciences, University of Torino, 10126, Turin, Italy.
  • Cabrol C; Department of Pediatrics, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia.
  • Cilio MR; Centre de Génétique Humaine, Centre Hospitalier Régional Universitaire, Université de Franche-Comté, Besançon, France.
  • Cornet MC; Department of Pediatrics, Division of Pediatric Neurology Saint-Luc University Hospital, and Institute of Neuroscience (IoNS), Catholic University of Louvain, Brussels, Belgium.
  • Coubes C; Department of Pediatrics, Division of Neonatology, University of California San Francisco, San Francisco, CA, USA.
  • Danhaive O; Département de Génétique Médicale, Maladies Rares et Médecine Personnalisée, Hôpital Arnaud de Villeneuve, CHU de Montpellier, Montpellier, France.
  • Delague V; Division of Neonatology, Saint-Luc university Hospital, and Institut of Clinical and Experimental Research (IREC), Bruxelles, Belgium.
  • Denommé-Pichon AS; Aix Marseille Univ, INSERM, Marseille Medical Genetics Center, MMG, Marseille, France.
  • Di Giacomo MC; UMR 1231 GAD, Inserm, Université de Bourgogne Franche Comté, Dijon, France.
  • Doco-Fenzy M; Unité Fonctionnelle Innovation en Diagnostic Génomique des Maladies Rares, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.
  • Engels H; Medical Genetics Service and Laboratory of Cytogenetics, SIC Anatomia Patologica, "San Carlo" Hospital, 85100, Potenza, Italy.
  • Cremer K; CHU Reims, Service de Génétique, Reims, France.
  • Gérard M; CHU de Nantes, service de génétique médicale, Nantes, France.
  • Gleeson JG; L'institut du thorax, INSERM, UNIV Nantes, Nantes, France.
  • Heron D; Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany.
  • Goffeney J; Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany.
  • Guimier A; Clinical Genetics, Côte de Nacre University Hospital Center, Caen, France.
  • Harms FL; University of California San Diego, Department of Neurosciences, Rady Children's Institute for Genomic Medicine, San Diego, CA, 92037, USA.
  • Houlden H; Department of Genetics, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne University, Paris, France.
  • Iacomino M; Service de neuropédiatrie, Centre Hospitalier Régional Universitaire, Université de Franche-Comté, Besançon, France.
  • Kaiyrzhanov R; Service de Médecine Génomique des Maladies Rares, Hôpital Necker Enfants Malades, Institut Imagine et Université Paris-Cité, Paris, France.
  • Kamien B; Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Karimiani EG; Department of Neuromuscular Diseases UCL Queen Square Institute of Neurology, University College London, London, UK.
  • Kraus D; Unit of Medical Genetics, IRCCS Instituto Giannina Gaslini, Genova, Italy.
  • Kuentz P; Department of Neuromuscular Diseases UCL Queen Square Institute of Neurology, University College London, London, UK.
  • Kutsche K; Genetic Services of Western Australia, King Edward Memorial Hospital, Perth, WA, 6008, Australia.
  • Lederer D; Department of Molecular Genetics, Next Generation Genetic Polyclinic, Mashhad, Iran.
  • Massingham L; Molecular and Clinical Sciences Institute, St. George's, University of London, Cranmer Terrace, London, SW17 0RE, UK.
  • Mignot C; Department of Neurology, Schneider Children's Medical Center of Israel, Petah Tiqva, Israel.
  • Morris-Rosendahl D; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 6997801, Israel.
  • Nagarajan L; UMR 1231 GAD, Inserm, Université de Bourgogne Franche Comté, Dijon, France.
  • Odent S; Oncobiologie Génétique Bioinformatique, PCBio, CHU Besançon, Besançon, France.
  • Ormières C; Institute of Human Genetics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
  • Partlow JN; Institute for Pathology and Genetics, 6040, Gosselies, Belgium.
  • Pasquier L; Division of Medical Genetics, Department of Pediatrics, Hasbro Children's Hospital, Providence, RI, USA.
Eur J Hum Genet ; 31(9): 1023-1031, 2023 09.
Article en En | MEDLINE | ID: mdl-37344571
ABSTRACT
BRAT1 biallelic variants are associated with rigidity and multifocal seizure syndrome, lethal neonatal (RMFSL), and neurodevelopmental disorder associating cerebellar atrophy with or without seizures syndrome (NEDCAS). To date, forty individuals have been reported in the literature. We collected clinical and molecular data from 57 additional cases allowing us to study a large cohort of 97 individuals and draw phenotype-genotype correlations. Fifty-nine individuals presented with BRAT1-related RMFSL phenotype. Most of them had no psychomotor acquisition (100%), epilepsy (100%), microcephaly (91%), limb rigidity (93%), and died prematurely (93%). Thirty-eight individuals presented a non-lethal phenotype of BRAT1-related NEDCAS phenotype. Seventy-six percent of the patients in this group were able to walk and 68% were able to say at least a few words. Most of them had cerebellar ataxia (82%), axial hypotonia (79%) and cerebellar atrophy (100%). Genotype-phenotype correlations in our cohort revealed that biallelic nonsense, frameshift or inframe deletion/insertion variants result in the severe BRAT1-related RMFSL phenotype (46/46; 100%). In contrast, genotypes with at least one missense were more likely associated with NEDCAS (28/34; 82%). The phenotype of patients carrying splice variants was variable 41% presented with RMFSL (7/17) and 59% with NEDCAS (10/17).
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedades Neurodegenerativas / Epilepsia Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Eur J Hum Genet Asunto de la revista: GENETICA MEDICA Año: 2023 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedades Neurodegenerativas / Epilepsia Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Eur J Hum Genet Asunto de la revista: GENETICA MEDICA Año: 2023 Tipo del documento: Article País de afiliación: Francia